Reminder: Starting January 1, 2015, Novolin, Novolog, Lantus and Levemir will be the insulin products with preferred brand status for Blue Cross and Blue Shield of Illinois, Blue Cross and Blue Shield of Montana, Blue Cross and Blue Shield of New Mexico, Blue Cross and Blue Shield of Oklahoma, and Blue Cross and Blue Shield of Texas Commercial formularies. (Novolin and Novolog will be the insulin products with preferred brand status for Exchange Affected Market formularies.)
Please download the PDF file listed below for details.